PRA adds a biotech vet to its board amid an expansion effort

Ocera CEO Linda Grais

PRA Health Sciences ($PRAH) added biotech veteran Linda Grais to its board of directors, broadening its managerial suite as it works to grow around the globe.

Grais is the CEO of Ocera Therapeutics ($OCRX), at work on a Phase II treatment for liver disease. Before taking the helm of Ocera in 2012, she served as a managing partner at biotech investor InterWest. Prior to joining the VC firm, Grais founded and ran SGX Pharmaceuticals until Eli Lilly ($LLY) acquired it in 2008.

Joining PRA's 7-member board, Grais will sit on the audit committee and bring "her extensive experience in the healthcare field as a physician, attorney and biotechnology entrepreneur" to the company's brain trust, CEO Colin Shannon said in a statement.

Meanwhile, PRA is expanding its operation with a particular focus on Pennsylvania, adding about 250 jobs over the next few years as it completes a $4 million new project. The company's latest recruitment effort follows the debut of what PRA calls its Candidate Experience initiative, a multiplatform effort to identify and recruit qualified nurses, study coordinators and healthcare workers who may thrive as clinical research associates.

- read the statement

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.